ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Neuvogen for CD8 ImmunoPET Technology
Shots:
- ImaginAb to receive license fees and other contingent payments and will partner with Neuvogen to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents in their clinical trials of therapeutic vaccines
- ImaginAb will provide technical- clinical & regulatory support to Neuvogen. ImaginAb's PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients
- The agreement gives Neuvogen access to highly specific and precise imaging of the presence of CD8 T Cells in solid tumors
Ref: PRNewswire | Image: ImaginAb
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com